October's LRG newsletter features artist Douglas Morgan, who found himself with a rare GIST mutation and no treatment options until an innovative oncologist and a compassionate gesture by a pharmaceutical company gave him a chance to receive a unique treatment.
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Pharma Panel: Overview of Promising Trials for GIST "Addressing Key Mechanisms of Tumor Drug Resistance" Deciphera Pharmaceuticals view all Life Fest 2018 Videos
By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
Results from a Continuation Trial of SU11248 in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST)
Here are the trial results from a Continuation Trial of SU11248 in Patients with Imatinib-resistant GIST.